Connective tissue growth factor (CTGF) has a major role in development of fibrosis and in the woundhealing process. Microarray analysis of 44 classical Hodgkin lymphoma (cHL) samples showed higher CTGF messenger RNA expression in the nodular sclerosis (NS) than in the mixed cellularity (MC) subtype. When analyzed by immunohistochemical analysis, Hodgkin-Reed-Sternberg (H-RS) cells and macrophages in 23 cHLs and "popcorn" cells in 2 nodular lymphocyte predominant Hodgkin lymphomas showed expression of CTGF protein correlating with the extent of fibrosis. In NS, CTGF was also expressed in fibroblasts and occasional lymphocytes. Malignant cells in 32 samples of various non-Hodgkin lymphomas were negative for CTGF. A staining pattern of stromal cells similar to that of NS cHL was seen in anaplastic large cell lymphoma. Macrophages stained positively in Burkitt lymphomas and in some mantle cell lymphomas. The high occurrence of fibrosis in cHL may be related to CTGF expression by malignant H-RS cells.
Connective tissue growth factor (CTGF/CCN2) is a member of the regulatory protein family referred to under the CCN acronym (for Cysteine-rich protein [Cyr61/CCN1], Connective tissue growth factor [CTGF/ CCN2], and Nephroblastoma overexpressed gene [nov/ CCN3]). The CCN family is a group of 6 secreted proteins: CCN1 through 3 and the Wnt (Wg [wingless] and Int)-induced secreted proteins (Wisp) 1 through 3, which specifically associate to the extracellular matrix (ECM). They are involved in biologic processes such as proliferation, adhesion, apoptosis, and angiogenesis. 1 CTGF has a major role in the development of fibrosis and the wound-healing process. 2 CTGF was at first described as an inducer of DNA synthesis and of migration of fibroblasts. 3 Recently, it has been shown to be involved in tumor desmoplasia, ie, malignancy-related deposition of ECM. 1 In vitro studies, mainly on fibroblasts, have provided a functional basis for the correlation between expression profiles of transforming growth factor β (TGF-β) and CTGF. 1, 4 The CTGF promoter sequence contains a TGF-β-responsive element. 5 Classical Hodgkin lymphoma (cHL) is a B-cell lymphoma defined by the presence of malignant HodgkinReed-Sternberg (H-RS) cells. H-RS cells are scarce in the tumor (usually ~1%). The tumor tissue mainly consists of reactive cells such as T cells, macrophages, eosinophils, mast cells, and fibroblasts. The H-RS cells are thought to recruit these cells by secreting inflammatory proteins and cytokines, thereby orchestrating the growth of the tumor. 6 There are 4 subtypes of cHL, 2 of which constitute approximately 90% of all cHL cases (nodular sclerosis [NS] and mixed cellularity [MC]). 7 The cellular infiltrate distinguishes NS from MC. NS has a higher number of CD4+ lymphocytes and regulatory T cells and is associated with eosinophilia. [8] [9] [10] However, the most striking characteristic of NS in comparison with MC is the presence of ECM deposits: collagen-rich fibrotic bands surrounding the nodules where the inflammatory and malignant cells reside. MC is characterized by a lack of ECM deposits and the presence of epithelioid macrophages. Lymphocytes and H-RS cells have been described to express TGF-β. 11, 12 However, the expression of CTGF has not been previously studied in cHL.
Based on expression profiling of 44 cHL biopsy specimens (25 NS and 19 MC), we identified subtype-specific gene expression patterns. 13 Several genes typical of MC could be assigned to the inflammatory phase in wound healing, while genes expressed in NS overlap with those active in second-and third-phase wound healing, [14] [15] [16] including the high expression of CTGF messenger RNA. Wound healing can be divided into 3 phases: the inflammatory phase, the proliferative phase, and the remodeling phase. The inflammatory phase is characterized by an increase of stimulated epithelial and endothelial cells, which produce cytokines and chemokines. These, in turn, recruit and activate neutrophils, macrophages, T cells, B cells, and eosinophils. In the subsequent proliferative phase, macrophages are activated. This process leads to degradation of the contemporary ECM and subsequent production of new ECM components by myofibroblasts. This is followed by the remodeling and maturation phase when collagen fibers become more organized and scar tissue is eliminated. 15 Expression of CTGF was also analyzed by immunohistochemical analysis. The H-RS cells, regardless of cHL subtype, expressed CTGF, as did some macrophages and fibroblasts in the infiltrate. High CTGF expression was associated with the NS subtype. Malignant B cells in a broad series of non-Hodgkin lymphomas (NHLs) were negative.
Materials and Methods

Tumor Samples and Cell Lines
The cell lines used in this study were cHL-derived cell lines L428, L1236, and KMH2 and Burkitt lymphoma (BL) cell lines Raji, Ramos, DG75, and MutuI. [17] [18] [19] [20] [21] L1236 and KMH2 are derived from MC cases, and L428 is derived from an NS case. Raji and MutuI are Epstein-Barr virus (EBV)+ BL cell lines, whereas Ramos and DG75 are EBV-. Cell lines were cultured in RPMI medium (Sigma, St Louis, MO) supplemented with 10% calf serum and 1% Pen/Strep at 37°C and at 5% carbon dioxide pressure.
Samples of fresh lymph node biopsies from patients with cHL were snap frozen in liquid nitrogen and stored at -80°C. We included 44 cHL tumors, 25 cases of NS and 19 cases of MC diagnosed according to the World Health Organization classification. 7 Two samples from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) were also studied. EBV status was defined by immunohistochemical detection of latent membrane protein-1 and EBV-encoded RNA in situ hybridization as previously described. 22 Paraffin-embedded tissue of 21 tumors that were included in the gene expression study and 2 additional NS cases were available for further validation by immunohistochemical analysis (see later text).
A series of paraffin-embedded diagnostic samples from 32 patients with NHL was also included: 5 BLs, 6 anaplastic large cell lymphomas, 4 mantle cell lymphomas, 4 mucosalassociated lymphoid tissue lymphomas, 4 follicular lymphomas, 3 diffuse large B-cell lymphomas, 4 B-cell chronic lymphocytic leukemias, and 2 immunocytomas. Biopsy specimens of reactive nonmalignant tonsil and lung tissues were used as control samples.
This 
RNA Preparation and Evaluation
RNA extraction from both cell lines and biopsy specimens was performed with the Ultraspec-II RNA isolation system (Biotecx, Houston, TX) according to the manufacturer's protocol or with the Qiagen RNeasy minikit (Qiagen, Valencia, CA) with minor modification: when RNA was extracted from the tumors, the amount of lysis buffer was increased to 500 μL.
Microarrays
Labeling and hybridization were performed according to the standard Affymetrix protocols at the KI Microarray Core Facility, Novum, Huddinge, Sweden (http://www. bea.ki.se/affymetrix/), or at Cancer Research UK (CRUK), Birmingham University, Birmingham, England. The tumors were arrayed using 2 Affymetrix array designs: the U133+2 array containing approximately 39,500 genes and the Human Genome Focus array containing 8,793 genes (including internal controls), respectively. The probe set on the Human Genome Focus array is also represented on the U133+2 arrays, which makes them comparable.
Bioinformatics
We used the Affymetrix GeneChip Operating Software (Affymetrix, Santa Clara, CA) to convert the CEL files into absolute statistical signals, and the samples were scaled to the average signal of 100. The first step in the analysis was to assess the quality reports. The following criteria were applied: average present call more than 40% for all genes, background less than 90, background standard deviation less than 2, scaling factor less than 2, and degradation of glyceraldehyde-3-phosphate dehydrogenase as measured by 3'/5'-end probes ratio less than 2. All samples that fulfilled 4 of 5 criteria were considered adequate for further analysis. The CEL files were converted and normalized using the robust multichip average method (RMA quintile normalization) for further analysis. 23 Differentially expressed genes were identified using significant analysis of microarray with a false-positive cutoff value of 5% and a 1.70-fold change. 24 
Immunohistochemical Analysis
Immunohistochemical analysis was performed using an immunoperoxidase method as previously described. 25 CTGF (goat sc-14939, Santa Cruz, Santa Cruz, CA) was applied diluted 1:100 in Tris-buffered saline with 5% bovine serum albumin.
Cytocentrifuged Specimens
The cells were deposited on glass slides in a Cytospin (Shandon, Thermo Fisher Scientific, Waltham, MA) cytocentrifuge at 1,200 rpm for 5 minutes, fixed in methanolacetone (1:1), and stored at -20° C. After rehydration for 5 minutes in phosphate-buffered saline and then 5 minutes incubation with phosphate-buffered saline-0.1% Triton (Merck, Darmstadt, Germany), the slides were incubated with the primary antibody diluted in 5% bovine serum albumin for 1 hour. The staining procedure was performed according to published protocols. 25 
Results
Gene Expression Analysis
The messenger RNA expression level of 205 genes differed significantly between NS and MC tumor biopsy specimens. Of these, 152 genes showed higher expression in the NS subtype and 53 genes showed higher expression in the MC subtype, as identified by significant analysis of microarray. Genes expressed at a higher level in the NS subtype included those that encoded proteins involved in the deposit or remodeling of ECM, TGF-β and its signaling partners, as well as various inflammatory molecules. Examples of these genes are given in ❚Table 1❚. In a survey of several of these subtype-specific genes by immunohistochemical analysis, we found that CTGF was the only one expressed in the malignant H-RS cells. Therefore, we decided to explore the expression of CTGF further. were of the MC subtype. Group II included 3 MC and 4 NS tumors. One MC case in group II showed expression of CTGF in all macrophages. These were evenly distributed in the whole section, but no positive fibroblasts were found. All tumors but 1 in group III were of the NS subtype.
Expression of CTGF
The malignant "popcorn" cells of the 2 studied NLPHL cases showed weak granular staining similar to that in some of the H-RS cells. Also, both cases of NLPHL showed a similar staining pattern in the bystander cells to that in MC cHL with low or no fibrosis, ie, positivity in occasional macrophages.
bystander cells, 3 groups of tumors could be distinguished (Image 1). In group I, a few dispersed macrophages were positive (Image 1D). Group II showed distinct positive staining of most macrophages ❚Image 1E❚. Tumors in group III displayed intense positive staining of macrophages, fibroblasts, and occasional lymphocytes ❚Image 1F❚. The tumors in group III showed a higher level of fibrosis. In most tumors, regardless of subtype, positive macrophages clustered around the fibrotic bands and ECM deposits. However, positive macrophages were also scattered throughout the whole tissue in some tumors. In group I, all tumors but 1 
CTGF Expression in NHLs
The expression of CTGF was evaluated by using the same antibody in diagnostic biopsy specimens from 34 NHLs. We could not find CTGF expression in the malignant cells of any NHLs. However, bystander cells were variably positive. Anaplastic large cell lymphoma showed similar patterns of expression in bystander cells as in cHL ❚Image 2❚. In BL, the characteristic "starry-sky" macrophages were positive ❚Image 3A❚. Of 4 mantle cell lymphomas, 2 had areas with positive large macrophages, reminiscent of the starry-sky macrophages ❚Image 3B❚. In 2 of 4 B-cell chronic lymphocytic leukemia samples, positive macrophages were found clustered in a small area of the tumor ❚Image 3C❚. In the 4 mucosal-associated lymphoid tissue lymphomas, the epithelium was CTGF+. No positive cells were found in the 4 follicular lymphomas, the 3 diffuse large B-cell lymphomas, or the 2 immunocytomas.
CTGF Expression in Lymphoma-Derived Cell Lines
The cHL-derived cell lines L1236, L428, and KMH2 expressed CTGF to variable degrees. In L1236 and L428, almost all cells were positive, whereas 25% of the KMH2 cells were positive ❚Image 4❚. Three BL cell lines (DG75, MutuI, and Ramos) were negative, whereas the BL cell line Raji showed 25% positive cells.
Discussion
We found that CTGF was expressed in malignant cells regardless of cHL subtype or EBV status. In contrast, CTGF was not detected in the malignant cells of other mature B-NHLs. However, it has been reported to be strongly expressed in many cases of B-cell acute lymphoblastic leukemia and related to a worse prognosis. 26, 27 CTGF is a connective tissue regulating protein, which is expressed during wound healing and has an important role in ECM generation. Thus, it was not surprising that we found this gene highly expressed in the cHL NS subtype. By immunohistochemical staining, we could show that fibroblasts and macrophages also expressed CTGF in NS cHL and that the staining intensity correlated with level of fibrosis. Fibroblasts were positive within the fibrotic streaks in NS tumors. Positive macrophages were found in NS and MC Hodgkin lymphomas. In most fibrotic tumors, regardless of subtype, macrophages clustered around the fibrotic bands. In some tumors, positive macrophages were the M2 type. M2 macrophages are linked to tissue remodeling and induce epithelial cell migration and proliferation. 31 Considering the high expression of interleukins 13 and 10 in cHL, 32 NS-associated macrophages are likely to be the M2 type. In sarcomas and follicular lymphomas, another type of tumor-associated macrophage has been identified. These lack the M2 polarization. 33, 34 We found CTGF expression in macrophages in different types of NHL, but never in the malignant cells.
There is an intriguing connection between CTGF and apoptosis, implying that CTGF expression might confer a survival advantage. When CTGF was overexpressed in the breast cancer cell line MCF-7 or aortic smooth muscle cells, it induced apoptosis. 35, 36 However, in other experimental systems, CTGF protected against apoptosis. 37 Expression of CTGF has been implied as a prognostic marker in several scattered throughout the tissue. This was especially true for 3 MC tumors with ECM deposition but no fibrotic streaks. Staining patterns characteristic for MC and for NS could be clearly identified. Because fibrosis in cHL can be used as a measure of tumor desmoplasia, our findings are in line with previous studies indicating a link between CTGF expression and tumor desmoplasia. 28 Desmoplastic response refers to the phenomenon that occurs in many solid tumors in which stromal myofibroblasts synthesize and deposit ECM.
The variable, sometimes massive infiltration of macrophages in cHL deserves more attention. Tumor-associated macrophages are becoming a well-established phenomenon in several nonhematopoietic malignancies. In some epithelial tumors such as bladder and breast cancer, macrophage infiltration is associated with a worse prognosis. 29, 30 Macrophages found in these tumors are often polarized to epithelial cell cancers, including lung, breast, and colon cancer; however, in some studies, high expression of CTGF was related to better survival, and in other studies CTGF conferred resistance to cytostatics. [38] [39] [40] It should be of interest to further explore the possible functional role of CTGF in the pathogenesis of cHL, considering its expression in H-RS cells and in bystander cells in cHL, its association with the NS subtype, and its range of relevant functions. High occurrence of fibrosis in cHL may be related to CTGF expression by malignant H-RS cells. 
G E F
The Burkitt lymphoma-derived cell lines DG75, MutuI, and Ramos were negative (D, ×40; E, ×40; and F, ×40; respectively), but Raji showed approximately 25% positive cells (G, ×40).
